IL-8 reduced tumorigenicity of human ovarian cancer in vivo due to neutrophil infiltration

Journal of Immunology

Volumn 164, Issue 5, 2000, Pages 2769-2775

  Lee, Li Fen ^a,c   Hellendall, Ronald P ^a   Wang, Ying ^a   Haskill, J Stephen ^a   Mukaida, Naofumi ^b   Matsushima, Kouji ^b   Ting, Jenny P Y ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b KANAZAWA UNIVERSITY   (Japan)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DNA; INTERLEUKIN 8; NEUTRALIZING ANTIBODY;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; NEUTROPHIL; NORTHERN BLOTTING; OVARY CANCER; PRIORITY JOURNAL;

EID: 0034163318     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.164.5.2769     Document Type: Article

References (44)

1. Colombo, M. P., and G. Forni. 1994. Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? Immunol. Today 15:48.
2. Gansbacher, B., R. Bannerji, B. Daniels, K. Zier, K. Cronin, and E. Gilboa. 1990. Retroviral vector-mediated γ-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res. 50:7820.
3. Colombo, M. P., G. Ferrari, A. Stoppacciaro, M. Parenza, M. Rodolfo, F. Mavilio, and G. Parmiani. 1991. Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. J. Exp. Med. 173:889.
4. Columbek, P. T., R. Azhari, M. Elizabeth, H. I. Levitsky, A. Lazenby, K. Leong, and D. M. Pardoll. 1993. Controlled release, biodegradable cytokine depots: a new approach in cancer vaccine design. Cancer Res. 53:5841.
5. McBride, W. H., G. D. Dougherty, A. E. Wallis, J. S. Economou, and C. S. Chiang. 1994, Interleukin-3 in gene therapy of cancer. Folia Biol. 40:62.
6. Tepper, R. I., P. K. Pattengale, and P. Leder. 1989. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 57:503.
7. Mullen, C. A., M. M. Coale, A. T. Levy, W. G. Stetler-Stevenson, L. A. Liotta, S. Brandt, and R. M. Blaese. 1992. Fibrosarcoma cells transduced with the IL-6 gene exhibit reduced tumorigenicity, increased immunogenicity, and decreased metastatic potential. Cancer Res. 52:6020.
8. + T cell-dependent tumor rejection. J. Exp. Med. 174:1291.
9. Berman, R. M., T. Suzuki, H. Tahara, P. D. Robbins, S. K. Narula, and M. T. Lotze. 1996. Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice. J. Immunol. 157:231.
10. Musiani, P., A. Allione, A. Modica, P. L. Lollini, M. Giovarelli, F. Cavallo, F. Belardelli, G. Fomi, and A. Modesti. 1996. Role of neutrophils and lymphocytes in inhibition of a mouse mammary adenocarcinoma engineered to release IL-2, IL-4, IL-7, IL-10, IFN-α, IFN-γ, and TNF-α. Lab. Invest. 74:146.
11. Trinchieri, G., and P. Scott. 1994. The role of interleukin 12 in the immune response, disease and therapy. Immunol. Today 15:460.
12. Blankenstein, T., Z. Qin, K. Uberla, W. Muller, H. Rosen, H. Volk, and T. Diamantstein. 1991. Tumor suppression after tumor cell-targeted tumor necrosis factor a gene transfer. J. Exp. Med. 173:1047.
13. Ferrantini, M., E. Proietti, L. Santodonato, L. Gabriele, M. Peretti, I. Plavec, F. Meyer, T. Kaido, I. Gresser, and F. Belardelli. 1993. α1 interferon gene transfer into metastatic Friend leukemia cells abrogated tumorigenicity in immunocompetent mice: antitumor therapy by means of interferon-producing cells. Cancer Res. 53:1107.
14. Watanabe, Y., K. Kuribayash, K. Matsushima, K. Nishihara, E. Nakayama, T. Taniyama, and T. Sakata. 1989. Exogenous expression of mouse interferon gamma cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augumented anti-tumor immunity. Proc. Natl. Acad. Sci. USA 86: 9456.
15. Nakashima, E., A. Oya, Y. Kubota, N. Kanada, R. Matsushita, K. Takeda, F. Ichimura, K. Kuno, N. Mukaida, K. Hirose, et al. 1996. A candidate for cancer gene therapy: MIP-1a gene transfer to an adenocarcinoma cell line reduced tumorigenicity and induced protective immunity in immunocompetent mice. Pharm. Res. 13:1896.
16. Hoshino, Y., K. Hatake, T. Kasahara, Y. Takahashi, M. Ikeda, H. Tomizuka, T. Ohtsuki, M. Uwai, N. Mukaida, K. Matsushima, et al. 1995. Monocyte chemoattractant protein-1 stimulates tumor necrosis and recruitment of macrophages in tumors in tumor-bearing nude mice: increased granulocyte and macrophage progenitors in murine bone marrow. Exp. Hematol. 23:1035.
17. Singh, R. K., M. Gutman, R. Radinsky, C. D. Bucana, and I. J. Fidler. 1994. Expression of interleukin 8 correlates with the metastatic potential of human melanoma cells in nude mice. Cancer Res. 54:3242.
18. Smith, D. R., P. J. Polverini, S. L. Kunkel, M. B. Orringer, R. I. Whyte. M. D. Burdick, C. A. Wilke, and R. M. Strieter. 1994. Inhibition of interleukin 8 attenuates angiogenesis in bronchogenic carcinoma. J. Exp. Med. 179:1409.
19. Schadendorf. D., A. Moller, B. Algermissen, M. Worm, M. Sticherling, and B. M. Czarnetzki. 1993. IL-8 produced by human malignant melanoma cells in vitro is as an essential autocrine growth factor. J. Immunol. 151:2667.
20. Wang, J. M., G. Taraboletti, K. Matsushima, J. V. Damme, and A. Mantovani. 1990. Induction of hepatocytic migration of melanoma cells by neutrophil activating protein/IL-8. Biochem. Biophys. Res. Commun. 169:165.
21. Arenberg, D. A., S. L. Kunkel, P. J. Polverini, M. Glass, M. D. Burdick, and R. M. Strieter. 1996. Inhibition of interleukin-8 reduces tumorigenicity of human non-small cell lung cancer in SCID mice. J. Clin. Invest. 97:2792.
22. Oppenheim, J. J., C. O. Zachariae, N. Mukaida, and K. Matsushima. 1991. Properties of the novel proinflammatory supergene "intercrine" cytokine family. Annu. Rev. Immunol, 9:617.
23. Wolpe, S. D., B. Sherry, D. Juers, G. Davatelis, R. W. Yurt, and A. Cerami. 1989. Identification and characterization of macrophage inflammatory protein 2. Proc. Natl. Acad. Sci. USA 86:612.
24. Lee, L.-F., A. K. Lofquist, C.-C. Schurer-Maly, C. Day, J. P.-Y. Ting, C. M. White, B. K. Martin, and J. S. Haskill. 1996. Taxol-dependent transcriptional activation of IL-8 expression in a subset of human ovarian cancer. Cancer Res. 56:1303.
25. Goldspiel BR. 1997. Clinical overview of the taxanes. Pharmacol. Ther. 5(Part 2): 110S.
26. Ezcurdia, L., S. L. Jovtis, E. Mickiewicz, G. Temperley, M. Rondinon, C. Blajman, F. S. Coppola, D. Lewi, E. Cazap, S. Breier, et al. 1997. Paclitaxel in platinum-resistant ovarian cancer patients: Argentine Multicenter Taxol Group. Semin. Oncol. 5(Suppl. 15):S15.
27. Martoni, A., N. Cacciari, B. Angelelli, C. Zamagni, and F. Pannuti. 1997. Chemotherapy of advanced ovarian cancer. Front. Biosci. 2:G20.
28. Lee, L.-F., J. S. Haskill, N. Mukaida, K. Matsushima, J. P.-Y. Ting. 1997. Identification of tumor-specific paclitaxel (Taxol)-responsive regulatory elements in the interleukin-8 promoter. Mol. Cell. Biol. 17:5097.
29. Chirgwin, J. M., A. E. Przybyla, R. J. MacDonald, W. J. Rutter. 1979. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 18:5294.
30. Sambrook, J., E. F. Fritsch, and T. Maniatis. Molecular Cloning: a Laboratory Manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, 1989.
31. DeForge, L. E., and D. G. Remick. 1991. Kinetics of TNF, IL-6, and IL-8 gene expression in LPS-stimulated human whole blood. Biochem. Biophys. Res. Commun. 174:18.
32. Hirose, K., M. Hakozaki, Y. Nyunoya, and Y. Kobayashi. 1995. Chemokine gene expression transfection into tumor cells reduced tumorigenicity in nude mice in association with neutrophilic infiltration. Br. J. Cancer 72:708.
33. Wang, J., M. Huang, P. Lee, K. Komanduri, S. Sharama, G. Chen, S. M. Dubinett. 1996. Interleukin-8 inhibits non-small cell lung cancer proliferation: a possible role for regulation of tumor growth by autocrine and paracrine pathways. J. Interferon Cytokine Res. 16:53.
34. Baggiolini, M., A. Walz, and S. L. Kunkel. 1989. Neutrophil-activating peptide-1/Interleukin 8, a novel cytokine that activates neutrophils. J. Clin. Invest. 84: 1045.
35. Leonard, E. J., A. Skeel, T. Yoshimura, K. Noer, S. Kutvirt, and D. Van Epps. 1990. Leukocyte specificity and binding of human neutrophil attractant/activating protein 1. J. Immunol. 144:1323.
36. Larsen, C. G., A. O. Anderson, E. Appella, J. J. Oppenheim, and K. Matsushima. 1989. The neutrophil-activating protein (NAP-1) is also chemotactic for T lymphocytes. Science 243:1464.
37. Schroeder, J.-M., M. Sticherling, H. H. Henicke, W. C. Preissner, and E. Christophers. 1990. IL-1a or tumor necrosis factor a stimulate release of three NAP-l/lL-8-related neutrophil chemotactic proteins in human dermal fibroblasts. J. Immunol. 144:2223.
38. Lloyd, A. R., and J. J. Oppenheim. 1992. Poly's lament: the neglected role of the polymorphonuclear neutrophil in the afferent limb of the immune response. Immunol. Today 13:169.
39. Koch, A. E., P. J. Polverini, S. L. Kunkel, L. A. Harlow, L. A. DiPietro, V. M. Elner, S. G. Elner, and R. M. Strieter. 1992. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 258:1798.
40. Strieter, R. M., S. L. Kunkel, V. M. Elner, C. L. Martonyi, A. E. Koch, P. J. Polverini, and S. G. Elner. 1992. Interleukin-8: a corneal factor that induces neovascularization. Am. J. Pathol. 141:1279.
41. Hock, H., M. Dorsch, U. Kunzendorf, Z. Qin, T. Diamantstein, and T. Blankenstein. 1993. Mechanism of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon γ. Proc. Natl. Acad. Sci. USA 90:2774.
42. Tepper, R. I., R. L. Coffman, and P. Leder. 1992. An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. Science 257:548.
43. Sakurai, T., S. Suzu, M. Yamada, M. Yanai, T. Kawashima, and K. Hatake. 1994. Induction of tumor necrosis factor (TNF) in mice by recombinant human macrophages colony-stimulating factor (rhM-CSF). Jpn. J Cancer Res. 85:80.
44. Douzono, M., M. Yamada, N. Yanai, T. Kawashima, K. Hatake, and K. Motoyoshi. 1995. Augmentation of cancer chemotherapy by preinjection of human macrophage colony-stimulating factor in L1210 leukemic cell-inoculated mice. Jpn. J. Cancer Res. 86:315.